ROVI announces an agreement with Biogaran for the marketing of its enoxaparin biosimilar in France


No votes yet
 
Related
ROVI reports operating revenue growth of 8% and net profit growth of 83%
Today, Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialising and engaging in the...
9 min
27/07/2020